Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

Contributed by: PR Newswire

Tags

Keymed-Stapokibart

More Like This

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

Keymed Biosciences Announces 2023 Annual Results and Business Updates

Keymed Biosciences Announces Interim Results for First Half of 2024

NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases